DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sifalimumab
Sifalimumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Study Protocol
New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production Laura M
Advances in Interferon-Alpha Targeting-Approaches for Systemic Lupus Erythematosus Treatment
New Drug Therapies for Systemic Lupus
The Two Tontti Tudiul Lui Hi Ha Unit
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Ep 3178848 A1
246992764-Oa
Sifalimumab, an Anti-Interferon-Α Monoclonal
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
A Phase 1B Clinical Trial Evaluating Sifalimumab, an Anti-IFN-Α
Protein-Polymer-Drug Conjugates
Contents Volume 73 Issue 1 | ARD January 2014 Editorial Viewpoint
Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled Therapeutic Leadership; Spearheading Immunology Biologics
(INN) for Biological and Biotechnological Substances
Top View
RIA TA Strategy 2013
Rhode Island M Edical J Ournal
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Smoking Reduces the Efficacy of Belimumab in Mucocutaneous Lupus
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Delivering Value for Patients and Shareholders
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: an Overview
Astrazeneca Development Pipeline
Therapeutic Focus – Roche and Astrazeneca Take Interferon Approach to Lupus
Spotlight on Anifrolumab and Its Potential for the Treatment of Moderate-To-Severe Systemic Lupus Erythematosus
1 Reduction of Anterior Uveitis Flares in Patients with Axial
Trial of Anifrolumab in Active Systemic Lupus Erythematosus E.F
Biologic Therapies in Patients with Neuropsychiatric Systemic Lupus
Interferon Lambda in Inflammation and Autoimmune Rheumatic Diseases
Treatment of Rheumatoid Arthritis with Biological Agents —As a Typical and Common Immune-Mediated Inflammatory Disease
14 June 2021 Aperto
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Listes De DCI Proposées N'implique Aucune Recommandation En Vue De L'utilisation De La Substance Correspondante En Médecine Ou En Pharmacie
Biologic Therapy for Autoimmune Diseases: an Update Ziv Rosman1, Yehuda Shoenfeld2,3 and Gisele Zandman-Goddard1,3*
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Autoantibody and Cytokine Profiles During Treatment with Belimumab
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
Astrazeneca and Incyte Say IDO
Protocol Template FV 15.0
Safety, Tolerability and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
(12) Patent Application Publication (10) Pub. No.: US 2013/0309192 A1 Yurkovetskiy Et Al
GSK and the University of Manchester: Manchester Collaborative Centre for Inflammation Research - Translational Research Centre for Inflammatory Diseases
Compounds and Methods for Treating Inflammatory
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Upcoming Biological Therapies in Systemic Lupus Erythematosus
CAPTURE Study 2089
WO 2015/105926 Al 16 July 2015 (16.07.2015) P O PCT
Anti-Interferon Alpha Treatment in SLE Kyriakos A
Curriculum Vitae: Daniel J